Shares of Charles River Laboratories International Inc. advanced 9.06% to $163.36 Tuesday, on what proved to be an all-around ...

What Happened? Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after ...

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit ...

This was the stock's third consecutive day of losses.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...

Charles River Laboratories' share price has declined over 50% from its 2021 peak, presenting a potential buying opportunity for investors. The CRO company is facing headwinds from COVID's overhang ...

Charles River Labs seeks support for merger with WuXi Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal ...

What's happening. On May 6, Elliott and Charles River Laboratories entered into a cooperation agreement in which four incumbent directors won't seek re-election and the following four individuals ...

Charles River isn’t the only CRO to have struggled in the third quarter. Irish firm Icon reported third-quarter revenue of $2.03 billion, underperforming analyst expectations of $2.14 billion ...

Charles River Laboratories, a Wilmington, Mass., pharma services giant, is further expanding its footprint in Chicago as it takes up more space in one of the two buildings that make up Fulton Labs.

This was the stock's second consecutive day of losses.